You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The closing range uses available history since Sep 18, 2026; less than a full year is stored.
Churchill Capital Corp XIII appointed Paul Lapping as a director effective October 23, 2026, named him audit committee chair replacing William Sherman, and set cash compensation of $75,000 per annum for each director beginning October 1, 2026.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XIII
this stock
Churchill Capital Corp XIII
|
$419.38M | — | — | — | 0.0% |
|
VYLR
Vylor Inc.
|
$46.80B | — | — | — | 2.2% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$650.38M | +3.1% | — | — | 0.0% |
|
CCXI
Churchill Capital Corp XI
|
$627.18M | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Churchill Capital Corp XIII appointed Paul Lapping as a director effective October 23, 2026, named him audit committee chair replacing William Sherman, and set cash compensation of $75,000 per annum for each director beginning October 1, 2026.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XIII | -0.7% | -1.7% | — | -0.7% | — |
| SPY | -2.7% | -5.6% | -0.5% | -2.7% | +7.8% |
| vs SPY | +2.0% | +3.9% | — | +2.0% | — |
